APO RESEARCH · REPORT
Liver Fibrosis Drug
Liver fibrosis is the scarring process that represents the liver’s response to injury. In the same way as skin and other organs heal wounds through deposition of collagen and other matrix constituents so the liver repairs injury through the deposition of new collagen.
Product & engineering
Understand the product.
Liver fibrosis is the scarring process that represents the liver’s response to injury. In the same way as skin and other organs heal wounds through deposition of collagen and other matrix constituents so the liver repairs injury through the deposition of new collagen.
Selected research
Industry Research
Liver Fibrosis Drug Industry Research Report 2026
Market perspective
Liver fibrosis is the scarring process that represents the liver’s response to injury. In the same way as skin and other organs heal wounds through deposition of collagen and other matrix constituents so the liver repairs injury through the deposition of new collagen.
Global Liver Fibrosis Drug key players include Gilead, Biogen Idec, Merck KGaA, Bristol-Myers Squibb Company, Roche, etc. Global top five manufacturers hold a share over 60%.
North America is the largest market, with a share about 50%, followed by Europe and Japan, both have a share about 30 percent.
Read the full market overview
In terms of product, Nucleoside is the largest segment, with a share over 45%. And in terms of application, the largest application is Hepatitis, followed by Liver Fibrosis.
Report Scope
This report quantifies the global Liver Fibrosis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liver Fibrosis Drug Market by Company
Gilead
Biogen Idec
Merck KGaA
Bristol-Myers Squibb Company
Roche
Merck & Co.
Tri-Prime
Liver Fibrosis Drug Segment by Type
Nucleoside
Interferon
Other
Liver Fibrosis Drug Segment by Application
Hepatitis
Liver Fibrosis
Other
Liver Fibrosis Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Fibrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liver Fibrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Fibrosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liver Fibrosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liver Fibrosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liver Fibrosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nucleoside
- Interferon
- Other
Applications
- Hepatitis
- Liver Fibrosis
- Other
Companies covered
- Gilead
- Biogen Idec
- Merck KGaA
- Bristol-Myers Squibb Company
- Roche
- Merck & Co.
- Tri-Prime
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liver Fibrosis Drug Market Size (2021-2032)
- 2.2.2 Global Liver Fibrosis Drug Sales (2021-2032)
- 2.2.3 Global Liver Fibrosis Drug Market Average Price (2021-2032)
- 2.3 Liver Fibrosis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nucleoside
- 2.3.3 Interferon
- 2.3.4 Other
- 2.4 Liver Fibrosis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hepatitis
- 2.4.3 Liver Fibrosis
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liver Fibrosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liver Fibrosis Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Liver Fibrosis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Liver Fibrosis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Liver Fibrosis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liver Fibrosis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liver Fibrosis Drug, Product Type & Application
- 3.8 Global Manufacturers of Liver Fibrosis Drug, Established Date
- 3.9 Global Liver Fibrosis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Gilead
- 4.1.1 Gilead Company Information
- 4.1.2 Gilead Business Overview
- 4.1.3 Gilead Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Gilead Liver Fibrosis Drug Product Portfolio
- 4.1.5 Gilead Recent Developments
- 4.2 Biogen Idec
- 4.2.1 Biogen Idec Company Information
- 4.2.2 Biogen Idec Business Overview
- 4.2.3 Biogen Idec Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biogen Idec Liver Fibrosis Drug Product Portfolio
- 4.2.5 Biogen Idec Recent Developments
- 4.3 Merck KGaA
- 4.3.1 Merck KGaA Company Information
- 4.3.2 Merck KGaA Business Overview
- 4.3.3 Merck KGaA Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck KGaA Liver Fibrosis Drug Product Portfolio
- 4.3.5 Merck KGaA Recent Developments
- 4.4 Bristol-Myers Squibb Company
- 4.4.1 Bristol-Myers Squibb Company Company Information
- 4.4.2 Bristol-Myers Squibb Company Business Overview
- 4.4.3 Bristol-Myers Squibb Company Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol-Myers Squibb Company Liver Fibrosis Drug Product Portfolio
- 4.4.5 Bristol-Myers Squibb Company Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Liver Fibrosis Drug Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Merck & Co.
- 4.6.1 Merck & Co. Company Information
- 4.6.2 Merck & Co. Business Overview
- 4.6.3 Merck & Co. Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Merck & Co. Liver Fibrosis Drug Product Portfolio
- 4.6.5 Merck & Co. Recent Developments
- 4.7 Tri-Prime
- 4.7.1 Tri-Prime Company Information
- 4.7.2 Tri-Prime Business Overview
- 4.7.3 Tri-Prime Liver Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Tri-Prime Liver Fibrosis Drug Product Portfolio
- 4.7.5 Tri-Prime Recent Developments
5 Global Liver Fibrosis Drug Market Scenario by Region
- 5.1 Global Liver Fibrosis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liver Fibrosis Drug Sales by Region: 2021-2032
- 5.2.1 Global Liver Fibrosis Drug Sales by Region: 2021-2026
- 5.2.2 Global Liver Fibrosis Drug Sales by Region: 2027-2032
- 5.3 Global Liver Fibrosis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Liver Fibrosis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Liver Fibrosis Drug Revenue by Region: 2027-2032
- 5.4 North America Liver Fibrosis Drug Market Facts & Figures by Country
- 5.4.1 North America Liver Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liver Fibrosis Drug Sales by Country (2021-2032)
- 5.4.3 North America Liver Fibrosis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Liver Fibrosis Drug Market Facts & Figures by Country
- 5.5.1 Europe Liver Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liver Fibrosis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Liver Fibrosis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Liver Fibrosis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liver Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liver Fibrosis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liver Fibrosis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liver Fibrosis Drug Market Facts & Figures by Country
- 5.7.1 South America Liver Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liver Fibrosis Drug Sales by Country (2021-2032)
- 5.7.3 South America Liver Fibrosis Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Liver Fibrosis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liver Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liver Fibrosis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liver Fibrosis Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Liver Fibrosis Drug Sales by Type (2021-2032)
- 6.1.1 Global Liver Fibrosis Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Liver Fibrosis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Liver Fibrosis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Liver Fibrosis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liver Fibrosis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Liver Fibrosis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liver Fibrosis Drug Sales by Application (2021-2032)
- 7.1.1 Global Liver Fibrosis Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Liver Fibrosis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Liver Fibrosis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Liver Fibrosis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liver Fibrosis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Liver Fibrosis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liver Fibrosis Drug Value Chain Analysis
- 8.1.1 Liver Fibrosis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liver Fibrosis Drug Production Mode & Process
- 8.2 Liver Fibrosis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liver Fibrosis Drug Distributors
- 8.2.3 Liver Fibrosis Drug Customers
9 Global Liver Fibrosis Drug Analyzing Market Dynamics
- 9.1 Liver Fibrosis Drug Industry Trends
- 9.2 Liver Fibrosis Drug Industry Drivers
- 9.3 Liver Fibrosis Drug Industry Opportunities and Challenges
- 9.4 Liver Fibrosis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst